Low-Dose Naltrexone for Chronic Fatigue Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
This exploratory clinical trial tests low-dose naltrexone (LDN) for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). A remote trial approach is used, with eligibility open to the entire U.S.
Who Is on the Research Team?
Jarred Younger, PhD
Principal Investigator
University of Alabama at Birmingham
Are You a Good Fit for This Trial?
This trial is for individuals across the U.S. with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Specific eligibility criteria are not provided, but typically these would include age range, disease severity, and other health conditions.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Low-Dose Naltrexone
Trial Overview
The study explores different doses of Low-Dose Naltrexone (LDN) to treat ME/CFS. Participants will receive one of four possible doses: 1.5mg, 3.0mg, 4.5mg or 6.0mg to determine which works best.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants Receiving Low-Dose Naltrexone
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alabama at Birmingham
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.